1 Soaring Growth Stock to Buy and Hold for 10 Years [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Even a company whose shares are performing well can be attractive if there's plenty of upside, especially for those willing to stay in the game for a long time: Buy high, sell higher. Let's look at one corporation that has performed extremely well this year, but still looks like an excellent pick to hold onto over the next decade: Sarepta Therapeutics (NASDAQ: SRPT) . The biotech's shares are up by 62% year to date, but they haven't peaked yet. Sarepta just earned expanded approval Sarepta Therapeutics' most important marketed product so far, Elevidys, which it developed in collaboration with Roche , was approved in June of last year. What makes it the most important? Like all of the company's other drugs, it treats Duchenne muscular dystrophy (DMD), a rare, progressive neuromuscular disease. Unlike Sarepta Therapeutics' other products, Elevidys targets the underlying causes of DMD, the first approved gene therapy to do so. Eligible patients are likely to prefer this option. L
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- After a Big Win, Is Sarepta Therapeutics Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? [Yahoo! Finance]Yahoo! Finance
- Best Momentum Stocks to Buy for July 3rd [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $205.00 price target on the stock.MarketBeat
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
SRPT
Earnings
- 5/1/24 - Beat
SRPT
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- SRPT's page on the SEC website